Welcome to our dedicated page for Collegium Pharmaceutical news (Ticker: COLL), a resource for investors and traders seeking the latest updates and insights on Collegium Pharmaceutical stock.
Collegium Pharmaceutical, Inc. reports developments for a diversified biopharmaceutical business focused on commercial medicines for serious medical conditions. Its recurring news centers on JORNAY PM for ADHD, a neuropsychiatry growth business, and a responsible pain management portfolio that includes BELBUCA, Xtampza ER, Nucynta products and Symproic.
Company updates also cover operating and financial results, investor presentations, real-world data from pain medications, branded ADHD awareness campaigns, capital deployment, credit facilities, material agreements, shareholder voting matters and governance disclosures.
Collegium Pharmaceutical (Nasdaq: COLL) presented four poster sessions at the Annual PAINWeek National Conference, emphasizing its commitment to responsible pain management.
The presentations focused on the misuse and abuse of its products, particularly XTAMPZA® ER and Nucynta®, and provided real-world data on their diversion and non-medical use.
These efforts highlight the company's dedication to scientific research and education among healthcare providers, reinforcing its position in the pain management sector.
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced participation in two upcoming investor conferences in September 2021. The H.C. Wainwright 23rd Annual Global Investment Conference will feature a fireside chat on September 13, 2021, from 7:00 to 7:30 AM Eastern Time. Additionally, Collegium will present at the Cantor Virtual Global Healthcare Conference on September 28, 2021, from 8:00 to 8:30 AM Eastern Time. Both presentations will be accessible via the company's investor website, with replays available for 30 days post-event.
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced a $100 million share repurchase program, reflecting confidence in its growth and pain management portfolio. CEO Joe Ciaffoni emphasized their solid financial position and commitment to disciplined capital allocation. The program allows management flexibility in repurchasing shares based on market conditions and business needs, which could enhance shareholder value over time.
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) reported strong financial results for Q2 2021, with net income of $72.8 million and adjusted EBITDA of $40.1 million. Xtampza® ER achieved a market share of 31.5% in the oxycodone extended-release market, marking a significant growth from 30.6% in March 2021. However, the company adjusted its revenue guidance downwards for Xtampza ER to $140.0-$150.0 million, while increasing guidance for the Nucynta Franchise to $195.0-$205.0 million. A conference call is scheduled for today at 4:30 p.m. ET to discuss these results further.
Collegium Pharmaceutical (Nasdaq: COLL) will host a conference call on August 5, 2021, at 4:30 PM ET to discuss its financial results and corporate updates. Investors can participate by dialing (877) 407-8037 for U.S. callers or (201) 689-8037 for international participants. A live webcast will be available on the company's website, with a replay accessible approximately two hours post-event. Collegium is committed to responsible pain management and operates from Stoughton, Massachusetts.
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced the publication of a study titled, “Nonmedical Use of Xtampza® ER and Other Oxycodone Medications in Adults Evaluated for Substance Abuse Treatment,” in the Journal of Pain Research. The study emphasizes the importance of monitoring real-world data on the abuse and misuse of its products. Richard Malamut, M.D., highlighted the need for the medical community to access these data to make informed treatment decisions. However, the study underscores that Xtampza ER still carries a high potential for addiction, abuse, and misuse.
Collegium Pharmaceutical, a specialty pharmaceutical company focused on responsible pain management, will participate in the Jefferies Virtual Healthcare Conference on June 2, 2021, at 4:30 PM ET. The event will feature a fireside chat format, and the presentation will be accessible via live webcast on the company’s investor website. A replay will be available for about 30 days post-event. Collegium's headquarters is located in Stoughton, Massachusetts, and they aim to lead in pain management solutions.
Collegium Pharmaceutical, Inc. reported a net income of $15.7 million and Adjusted EBITDA of $45.3 million for Q1 2021. The company raised its full-year guidance for Nucynta franchise revenues from $175-$185 million to $185-$195 million and Adjusted EBITDA from $160-$170 million to $170-$180 million. Colleen Tupper has been appointed as the new CFO, effective May 24, 2021, succeeding Paul Brannelly. Xtampza ER's market share grew to 30.6%, supported by exclusive formulary wins. Collegium was named a 2021 Top Workplaces USA Company.
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced a conference call scheduled for May 6, 2021, at 4:30 p.m. ET. During this call, the company will discuss its financial results and provide a corporate update.
Investors can access the call by dialing (877) 407-8037 (U.S.) or (201) 689-8037 (International), referencing the "Collegium Pharmaceutical Q1 2021 Earnings Call." An audio webcast will be available on the company's website, with a replay accessible two hours post-event.
Collegium Pharmaceutical reported its 2020 financial results, marking its first full year of profitability, driven by Xtampza ER revenue growth and the acquisition of the Nucynta franchise. For the fourth quarter, net income reached $7.0 million compared to a $2.2 million loss in the same quarter of 2019. Xtampza ER generated $30.8 million in revenue, up 12% year-over-year, while Nucynta revenues fell 3% to $45.5 million. The company has reiterated its 2021 financial guidance, projecting Xtampza ER revenues between $155 million and $165 million.